ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

スルフィンピラゾン

Sulfinpyrazone

HCID 5342
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
57-96-5
標準SMILES
O=C1C(CCS(=O)c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1
InChIKey
MBGGBVCUIVRRBF-UHFFFAOYSA-N
分子式
C23H20N2O3S
平均分子量
404.5 g/mol
単同位体質量
404.11946368

概要

Sulfinpyrazone is a sulfoxide and a member of pyrazolidines. It has a role as a uricosuric drug.

名称と識別子

優先名称
Sulfinpyrazone
IUPAC
4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione
現地名
スルフィンピラゾン
英語名
(+/-)-Sulfinpyrazone
分子式
C23H20N2O3S
分子量
404.48

名称と別名

sulfinpyrazone57-96-5SulphinpyrazoneAnturaneAnturanDiphenylpyrazoneSulfoxyphenylpyrazolidineSulfinpyrazonAnturidinEnturenAnturanil1,2-Diphenyl-4-(2-(phenylsulfinyl)ethyl)pyrazolidine-3,5-dione
名称をさらに表示
(4α)-1,2-ジフェニル-4-[2-(フェニルスルフィニル)エチル]-3,5-ピラゾリジンジオンアンツラン(4β)-1,2-ジフェニル-4-[2-(フェニルスルフィニル)エチル]-3,5-ピラゾリジンジオン1,2-ジフェニル-4-[2-(フェニルスルフィニル)エチル]-3,5-ピラゾリジンジオンエンツレンスルフィンピラゾン1,2-ジフェニル-4-[2-(フェニルスルフィニル)エチル]ピラゾリジン-3,5-ジオンスルホキシフェニルピラゾリジンジフェニルピラゾンアンツリジン1,2-ジフェニル-4-(2-フェニルスルフィニルエチル)ピラゾリジン-3,5-ジオン1,2-ジフェニル-4-[2-(フェニルスルフィニル)エチル]-1H-ピラゾール-3,5(2H,4H)-ジオン(±)-スルフィンピラゾンスルフィンピラゾン (JAN)rac-(4α*)-1,2-ジフェニル-4-[2-(フェニルスルフィニル)エチル]-3,5-ピラゾリジンジオン1,2-ジフェニル-4β-[2-(フェニルスルフィニル)エチル]-3,5-ピラゾリジンジオン4-[2-(ベンゼンスルフィニル)エチル]-1,2-ジフェニルピラゾリジン-3,5-ジオン1,2-ジフェニル-4α-[2-(フェニルスルフィニル)エチル]-3,5-ピラゾリジンジオンg28315anturenenturang28,315
AnturanoUSAF GE-13SulfinpirazonaSulfinpyrazonum4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dioneDTXSID00236184-(Phenylsulfoxyethyl)-1,2-diphenyl-3,5-pyrazolidinedione1,2-Diphenyl-4-(2'-phenylsulfinethyl)-3,5-pyrazolidinedione

物性

構造計算による物性補完中

XLogP
2.3
極性表面積
76.9 Ų
水素結合供与体数
0
水素結合受容体数
4
回転可能結合数
6
重原子数
29
形式電荷
0
複雑度
571

実験および物理化学的性質

LogP · 2 件

2.4

3.56

Color/FormWHITE TO OFF-WHITE
Solubility · 5 件

SOL IN ETHYL ACETATE, CHLOROFORM

SLIGHTLY SOL IN WATER, ALC, ETHER, MINERAL OILS

SLIGHTLY SOL IN FATS

1 G SOL IN 10 ML ACETONE & 10 ML 0.5 N NAOH

For more Solubility (Complete) data for SULFINPYRAZONE (6 total), please visit the HSDB record page.

Human Drugs · 2 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point · 4 件

136-137 °C

136-137 °C

MELTING POINT: 130-133 °C /D-FORM, L-FORM/

136 - 137 °C

Physical DescriptionSolid
Stability/Shelf LifeSTABLE TO LIGHT & AIR
Dissociation Constants · 2 件

3.25

PKA: 2.8

Collision Cross Section · 2 件

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 70 reports by companies from 1 notifications to the ECHA C&L Inventory.

危険有害性情報

Other Safety InformationIMAP assessments - 3,5-Pyrazolidinedione, 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]-: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

毒性情報

Interactions · 3 件

...URICOSURIC ACTION /OF SULFINPYRAZONE/ IS ADDITIVE TO THAT OF PROBENECID & PHENYLBUTAZONE BUT IS MUTUALLY ANTAGONISTIC TO THAT OF SALICYLATES. ... POSSESSES ABILITY TO DISPLACE OTHER ORG ANIONS THAT ARE BOUND EXTENSIVELY TO PLASMA PROTEINS...THUS ALTERING THEIR DISTRIBUTION TO TISSUES & THEIR RENAL EXCRETION...

...SULFINPYRAZONE MAY POTENTIATE ACTIONS OF INSULIN & ORAL HYPOGLYCEMIC AGENTS...

SULFINPYRAZONE MAY DISPLACE SULFONAMIDES FROM PLASMA PROTEIN BINDING SITES...

Human Toxicity Excerpts · 2 件

HYPERSENSITIVITY REACTIONS, USUALLY A RASH WITH FEVER, DO OCCUR.../OCCASIONALLY/

SIDE EFFECTS INCL UPPER GI DISTURBANCES...&, RARELY, ANEMIA, LEUKOPENIA, AGRANULOCYTOSIS, & THROMBOCYTOPENIA.

安全データ

wgk
3
rtecs
UQ8575000
hs_code
2933194350

化学と産業

薬理情報

ATC Code · 2 件

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein Binding98-99%
Pharmacodynamics · 1 件

Sulfinpyrazone's pharmacologic activity is the potentiation of the urinary excretion of uric acid. It is useful for reducing the blood urate levels in patients with chronic tophaceous gout and acute intermittent gout, and for promoting the resorption of tophi.

Mechanism of Action · 2 件

Sulfinpyrazone is an oral uricosuric agent (pyrazolone derivative) used to treat chronic or intermittent gouty arthritis. Sulfinpyrazone competitively inhibits the reabsorption of uric acid at the proximal convoluted tubule, thereby facilitating urinary excretion of uric acid and decreasing plasma urate concentrations. This is likely done through inhibition of the urate anion transporter (hURAT1) as well as the human organic anion transporter 4 (hOAT4). Sulfinpyrazone is not intended for the treatment of acute attacks because it lacks therapeutically useful analgesic and anti-inflammatory effects. Sulfinpyrazone and its sulfide metabolite possess COX inhibitory effects. Sulfinpyrazone has also been shown to be a UDP-glucuronsyltransferase inhibitor and a very potent CYP2C9 inhibitor. Sulfinpyrazone is also known to be a cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor as well as an inhibitor of several multridrug resistance proteins (MRPs).

...IN SUFFICIENT DOSAGE IS POTENT INHIBITOR OF RENAL TUBULAR REABSORPTION OF URIC ACID. ...SMALL DOSES MAY REDUCE EXCRETION...PRESUMABLY BY INHIBITING SECRETORY BUT NOT REABSORPTIVE TRANSPORT. BY COMPETITIVE INHIBITION...REDUCES RENAL TUBULAR SECRETION OF OTHER ORG ANIONS...AS PAH /PARA-AMINOHIPPURIC/ & SALICYLIC ACID.

Biological Half-LifeApproximately 4-6 hours
Metabolism/Metabolites · 3 件

MOST OF DRUG (90%) IN URINE IS UNCHANGED; REMAINDER IS ELIMINATED AS N1-P-HYDROXYPHENYL METABOLITE...

.../IN RAT/ 28%...IN URINE & 24%...IN FECES & BILE WAS FOUND AS P-HYDROXYSULFINPYRAZOLE.

Sulfinpyrazone has known human metabolites that include Sulfinpyrazone sulfone.

関連反応

6 件
反応記録を作成
HRID 156978 の反応式
HRID 156978生成物として
HRID 833034 の反応式
HRID 833034反応物として
HRID 1577634 の反応式
HRID 1577634生成物として
HRID 1577636 の反応式
HRID 1577636生成物として
HRID 1577637 の反応式
HRID 1577637生成物として
HRID 1719691 の反応式
HRID 1719691反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
57-96-5
PubChem CID
5342
DTXSID
DTXSID0023618
ChEMBL
CHEMBL832
ChEBI
CHEBI:9342
UNII
V6OFU47K3W
EC Number
200-357-4
Nikkaji
J1.384F

193.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

193.18 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Other Experimental Properties · 3 件

CRYSTALS FROM CHLOROFORM & HEPTANE; CRYSTALS FROM ETHANOL /D-FORM/; CRYSTALS /L-FORM/

SPECIFIC OPTICAL ROTATION: +67.1 DEG @ 22 °C/D (C= 2.04 IN ETHANOL); +109.3 DEG @ 25 °C/D (C= 0.5 IN CHLOROFORM) /D-/

SPECIFIC OPTICAL ROTATION: -64.2 DEG @ 23 °C/D (C= 2.14 IN ETHANOL); -104.5 DEG @ 26 °C/D (C= 0.5 IN CHLOROFORM) /L-/

物理化学的性質

融点
136 · 136-137°
沸点
590.8 · 590.8±42.0 °C(Predicted)
比重(密度)
1.189 · 1.1890 (rough estimate)
屈折率
1.636 · 1.6360 (estimate)
貯蔵温度
Sealed in dry,Room Temperature
溶解性
96 %)に溶けにくい。アルカリ溶液に溶けます。 · 水に極めて溶けにくく、エタノール(96%)に溶けにくい。アルカリ溶液に溶けます。
外見
Solid
酸解離定数(Pka)
2.8 · pKa 2.8(H2O t = RT I undefined) (Uncertain)
色
オフホワイトからライトブラウン
水溶解度
2.601 g/L · 2.601g/L(22℃)
主な用途
洗浄剤化粧品食品および飲料法医学と毒物学パーソナルケア医薬品(低分子化合物)獣医
InChI
1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2
InChIKey
MBGGBVCUIVRRBF-UHFFFAOYSA-N
SMILES
O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c3ccccc3)c4ccccc4
CAS データベース
57 · 57-96-5(CAS DataBase Reference)
NISTの化学物質情報
Sulfinpyrazone(57-96-5)

化学的性質

化学的特性White or almost white powder.

risk_code
22
hazard_code
Xn
safety_code
36
Hazard Classifications
Acute Tox. 4 Oral
ストレージクラス
11 - Combustible Solids
有毒物質データの
57-96-5(Hazardous Substances Data)
MeSH Pharmacological ClassificationGout suppressants that act directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma.
Absorption, Distribution and Excretion · 5 件

...WELL ABSORBED AFTER ORAL ADMIN. ...BOUND TO PLASMA PROTEINS...98-99%. T/2... IN PLASMA AFTER IV INJECTION IS ABOUT 3 HR. AFTER ORAL ADMIN...URICOSURIC EFFECT MAY PERSIST FOR...10 HR. ALTHOUGH LITTLE...IS AVAILABLE FOR FILTRATION @ GLOMERULUS, IT IS SECRETED BY PROXIMAL TUBULE & UNDERGOES LITTLE PASSIVE BACK DIFFUSION...

APPROX HALF OF ORALLY ADMIN DOSE APPEARS IN URINE WITHIN 24 HR. MOST OF DRUG (90%) IN URINE IS UNCHANGED; REMAINDER IS ELIMINATED AS...METABOLITE...

...RAPIDLY EXCRETED IN MAN, TOGETHER WITH P-HYDROXYLATED METABOLITE. PLASMA T/2...IN RATS...16.2 HR, &...18% OF IP DOSE...WAS EXCRETED INTO URINE. PLASMA T/2 IN MAN...BETWEEN 1 & 3 HR. MAIN ROUTE OF ELIMINATION IN RAT...FECES (68% OF DOSE)...CONSIDERABLE PORTION...EXCRETED IN BILE WAS REABSORBED FROM INTESTINAL TRACT.

...SULFINPYRAZONE...IS EXCRETED IN URINE OF RATS TO ONLY A SMALL EXTENT. ... CLEARED FROM CIRCULATION MAINLY THROUGH BILE...NO EVIDENCE OF ENTERO-HEPATIC CIRCULATION MECHANISM.

UNCHANGED DRUG /IN RAT/ WAS PRINCIPAL EXCRETION PRODUCT & ONLY 28%...IN URINE & 24%...IN FECES & BILE WAS FOUND AS P-HYDROXYSULFINPYRAZOLE. FAILURE OF RAT TO EXCRETE A HIGH PROPORTION OF THE DRUG IN URINE MAY BE RELATED TO ITS LACK OF URICOSURIC PROPERTIES IN THIS SPECIES.

Cellular LocationsCytoplasm

用途と製造

UsesMEDICATION
Methods of Manufacturing · 2 件

SYNTHESIS: PFISTER, HAFLIGER, HELV CHIM ACTA 44, 232 (1961).

[2-(PHENYLSULFINYL)ETHYL]MALONIC ACID DIETHYL ESTER IS CONDENSED WITH HYDRAZOBENZENE WITH AID OF SOLN OF SODIUM ETHOXIDE IN ABSOLUTE ETHANOL. ... /ADDN/ XYLENE & HEATING @...130 DEG...ETHANOL...IS REMOVED. SULFINPYRAZONE IS ISOLATED BY SOLVENT EXTRACTION...& RECRYSTALLIZED FROM ETHANOL. US PATENT 2,700,671.

Formulations/PreparationsANTURANE (GEIGY). ORAL: CAPSULES 200 MG; TABLETS 100 MG.
応用分野 · 3 件

説明Sulfinpyrazone is soluble in alkaline solutions. Its synthesis is similar to that of phenylbutazone (Fig. 36.33). It produces its uricosuric effect in a manner similar to that of probenecid. A dose of 35 mg produces a uricosuric effect equivalent to that produced by 100 mg of probenecid, whereas 400 mg/day of sulfinpyrazone produces an effect comparable to that obtained with doses of 1.5 to 2 g of probenecid. It also possesses, not surprisingly, some of the properties of phenylbutazone. It is an inhibitor of human platelet prostaglandin synthesis at the cyclooxygenase step, resulting in a decrease in platelet release and a reduction in platelet aggregation. This antiplatelet effect suggests a role for sulfinpyrazone in reducing the incidence of sudden death, which can occur in the first year following a myocardial infarction; however, it lacks the analgetic and anti-inflammatory effects of phenylbutazone.

使用As an anti-inflammatory and uricosuric agent, its side effects were severe enough to preclude its continuous use in the treatment of chronic gout. Evaluation of several chemical congeners indicated that the phenylthioethyl analog of phenylbutazone had promising anti-inflammatory and uricosuric activity. A metabolite, the sulfoxide pyrazone, exhibited enhanced uricosuric activity. Interestingly, the corresponding sulfone does not appear to be a metabolite. Sulfinpyrazone lacks the clinically striking anti-inflammatory and analgesic properties of phenylbutazone.

一般的な説明Sulfinpyrazone (Anturane) produces its uricosuric action ina similar manner to that of probenecid and is indicated forthe treatment of chronic and recurrent gouty arthritis. It iswell absorbed with approximately 50% of the administereddose excreted as unchanged drug into the renal tubules. Therest of the drug is primarily metabolized via CYP2C9 intothe corresponding sulfide and sulfone metabolites, thus itcan potentiate the anticoagulant effect of warfarin.

上流・下流製品情報

上流原料

ナトリウムペルオキソ硫酸1,2-ジフェニル-4-[2-(フェニルチオ)エチル]-1H-ピラゾール-3,5(2H,4H)-ジオン炭酸水素ナトリウム酢酸エチル亜硫酸水素ナトリウム酢酸トルエン